Search Within

Heiko Schoder

  1. "Alison Moskowitz"
Formats
  1. Meeting Abstract (34)
  2. Journal Article (23)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (59)
  2. Department of Medicine (59)
  3. Hematologic Malignancies, Division of (59)
  4. Lymphoma (59)
  5. Molecular Imaging and Therapy Service (59)
  6. Radiology, Department of (59)

More Groups

People
  1. Alison Moskowitz (59)
  2. Andrew Zelenetz (43)
  3. Paul Hamlin (41)
  4. Steven Horwitz (41)
  5. Anita Kumar (39)
  6. Ariela Noy (39)

More People

Years
  1. 2025 (1)
  2. 2024 (6)
  3. 2023 (7)
  4. 2022 (5)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Blood (25)
  2. Hematological Oncology (7)
  3. Journal of Clinical Oncology (6)
  4. Blood Advances (4)
  5. Haematologica (3)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. Wiley Blackwell (7)
  3. American Society of Clinical Oncology (6)
  4. Ferrata Storti Foundation (3)
  5. Elsevier Science, Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (59)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory hodgkin lymphoma: A large multi-trial analysis based on individual patient data
    Meeting Abstract

    Driessen, J.; de Wit, F.; Herrera, A. F.; Zinzani, P. L. L.; LaCasce, A. S.; Moskowitz, C. H.; Garcia-Sanz, R.; Cole, P. D.; Fuchs, M.; Mueller, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes of adult T-cell leukemia/lymphoma with allogeneic stem cell transplantation: Single-institution experience
    Journal Article

    Epstein-Peterson, Z. D.; Ganesan, N.; Barker, J. N.; Drullinsky, P. R.; Ghione, P.; Jakubowski, A. A.; Kumar, A.; Moskowitz, A. J.; Noy, A.; Perales, M. A.; more...
    Leukemia and Lymphoma (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Predictive value of quantitative (18)F‐FDG‐PET‐CT radiomics analysis in 174 patients with relapsed/refractory classical Hodgkin lymphoma
    Meeting Abstract

    Driessen, J.; Zwezerijnen, G. J. C.; Schöder, H.; Moskowitz, A. J.; Kersten, M. J.; Moskowitz, C. H.; Eertink, J. J.; van de Brug, T.; de Vet, H. C. W.; Hoekstra, O. S.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save